EIGR | Eiger BioPharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.6600 - 1.9000
52 Week Range	1.1000 - 43.35
Beta	2.26
Implied Volatility	500.75%
IV Rank	85.27%
Day's Volume	129,682
Average Volume	113,731
Shares Outstanding	1,479,490
Market Cap	2,552,120
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-01-30

Valuation
Profitability
Growth
Health
P/E Ratio	-0.03
Forward P/E Ratio	N/A
EPS	-58.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	56
Country	USA
Website	EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

EIGR's peers: RDUS, RIGL

*Chart delayed

Analyzing fundamentals for EIGR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see EIGR Fundamentals page.

Watching at EIGR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on EIGR Technicals page.